# COS-AUDIT-002 Executive Audit Report

**Project:** CancerOS — breast cancer digital twin research prototype
**Scope:** all seven implementation phases · **Priority:** P0
**Mode:** audit-first, evidence-based, non-destructive — no architecture, spec, map, schema, or data changes made.
**Candidate:** `main` at `bd7b2c2`, clean worktree.
**Agent role:** Principal Research Engineering Lead and Independent Code Reviewer, with sequential specialist passes (self-review disclosed; no independent human experts, no fabricated team).
**Date (UTC):** 2026-11-01

## Verdict

The implementation is **coherent, maintainable, and honestly gated** — and **not yet ready for unrestricted formal testing or any release claim**. This audit issues **READY_WITH_RESTRICTIONS** (see `PRE-TESTING-READINESS.md`): fixture-scope testing may proceed; real-data, deployment, recovery, review, performance, participant, and live-model gates stay closed.

## Overall engineering assessment

The codebase matches the specified modular FastAPI + Next.js/TypeScript + PostgreSQL + private versioned objects + Redis + bounded CPU workers architecture. All seven phases are present with real modules behind them — governance, clinical/imaging ingestion, five simulation families, multimodal AI with a single bounded provider adapter, synchronized frontend, consolidated evaluation, and release operations. No competing architecture, duplicate provider, or silent scope expansion was found in the sampled paths.

## Architecture consistency

Established boundaries hold: domain modules free of `apps`/`services` imports, single `Provenance` owner, no frontend secret/storage APIs, canonical project APIs with generated clients, 49 migrations. Browser routes and REST routes are distinct. Optional capabilities (segmentation checkpoint, forecasting, Contributor mode, Kubernetes) are correctly disabled with explicit gates.

## Clean-code assessment (highest priority)

Maintainable overall with bounded, ordered refactoring ahead: 42 functions exceed 100 lines (route assembly, job processing), 83 duplicate local helper names (mostly narrow `session`/`detail` helpers — low risk), 20 files need `ruff format`, 17 broad `except Exception` sites (mostly fail-closed conversions that should be narrowed per site), and four frontend explorers over 340 lines (single-concern, no duplicated science in the browser). **No duplicated tumor-volume, provenance, simulation, or provider logic found** — each shared concern has one authoritative implementation. Full evidence in `CLEAN-CODE-AUDIT.md`.

## Scientific integrity assessment

Physical geometry is correctly derived: Decimal80 determinant volumes, handedness, round-trip ≤1e-5 mm, mask-authoritative measurements, RECIST kept distinct. Simulation rules, tolerances, determinism, and synthetic provenance verified on fixtures. Crucially, nothing real was fabricated: D02 stays blocked with zero eligible cases, forecast accuracy is Not evaluated, and hypothetical trajectories are never presented as predictions.

## Meta integration assessment

Secure and correctly closed: pinned endpoint, configured (not assumed) `muse-spark-1.3` default, no Contributor path, `SecretStr` storage, denied-by-default export with hash-pinned policies, zero-transport denial proven, strict output validation, bounded retries, withheld candidate prose, local-template fallback. **No live call was made by this audit**; the live smoke test remains a proposed explicit gate. No secrets printed, stored, or committed.

## Testing readiness

Fixture-scope suites are meaningful and pass: 19/19 fast Phase 6 suites and 20/20 Phase 7 audit suites verified in this audit; typecheck and lint pass. DB-backed suites were reused as frozen evidence where the audit time budget (240 s) or a missing local PostgreSQL instance prevented rerun — recorded explicitly, never assumed. Test fixtures, disposable-DB patterns, and evaluation cases exist and are correctly configured.

## Critical blockers

None found — no secret exposure, identity corruption, false provenance, destructive operation, or broken core workflow in the sampled paths. The release blockers are **missing-evidence gates** (D02 case, isolated restore, deployed target, qualified review, measured performance, participants), not active defects.

## Major strengths

1. Honest gating: every blocked capability says so with owner and evidence.
2. Single authoritative implementations for each scientific and security concern.
3. Fail-closed provider, grounding, and authorization design with adversarial coverage.
4. Full phase-by-phase evidence trail (105 evidence files) reconciling to a blocked-but-accurate readiness record.

## Recommended next actions

1. Stand up disposable PostgreSQL; rerun full DB-backed suites.
2. Work `REMEDIATION-BACKLOG.md` items 3–5 (function splits, helper consolidation, exception narrowing).
3. Close D02/restore/deployment/review/performance/participant gates through COS-103/104 with a new fingerprint.
4. Run the explicitly authorized live Model API smoke gate only after a verified export policy exists.
